Clinical Trial Update: A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating copanlisib combined with ibrutinib in mantle cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mantle Cell Lymphoma (MCL) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-14